YBYann Bertolani

Yann Bertolani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yann Bertolani has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intriguing choroidal lesions in Birdshot chorioretinopathy: a diagnostic and clinical dilemma

    by Yann Bertolani, Tetiana Goncharova, Eric Kirkegaard-Biosca, Laura Distefano

    Purpose: To report a case of intriguing choroidal lesions in a patient with Birdshot chorioretinopathy. Case presentation: A case report of a 51-year-old female with previous medical history of Birdshot chorioretinopathy presenting with de novo choroidal lesions, diffuse choroidal thickening and serous retinal detachment in the right eye is presented. Several medical evaluation visits were conducted, including ophthalmological and hematological follow-up. The multimodal imaging was suggestive of a lymphoproliferative process, presumably uveal lymphoid hyperplasia and the patient was referred to Hematology. A systemic work-up was conducted to rule out systemic malignancy and the choroidal biopsy was declined by the patient. The patient was treated with a short course of steroids due to an unrelated Bell’s palsy, with complete resolution of the choroidal thickening and the neurosensory detachment. After a 4-year follow-up, the patient remained asymptomatic with no signs of relapse in the multimodal imaging. Conclusion: As underline by this case report, uveal lymphoid hyperplasia may be considered in patients with Birdshot chorioretinopathy, emphasizing the importance of individualized management and long-term follow-up in such complex clinical scenarios.

  • Choroidal macrovessel mimicking a choroidal mass: A diagnostic challenge

    by T. Goncharova, M. Tort, Y. Bertolani, P. Buck, D. Oliver-Gutiérrez, E. Ros-Sánchez, A. Pueyo, M. Garrido-Marin, A. Boixadera

  • Open Access

    Efficacy and Safety of Open-Conjunctiva Ab Externo 63 µm vs. 45 µm XEN® Gel Stent in Glaucoma Surgery: One-Year Follow-Up

    by Yann Bertolani, Jaume Rigo-Quera, Laura Sánchez-Vela, Olivia Pujol-Carreras, Manuel Amilburu, Antonio Dou, Marta Castany

    Background: To compare the efficacy and safety of the XEN® 63 µm and 45 µm devices with the ab externo open conjunctiva with a 30G needle approach. Methods: A retrospective, non-randomized and single-center study was conducted. Consecutive eyes undergoing a XEN® 63 µm implant were compared with a matched cohort of cases with a XEN® 45 µm implant. Standalone and combined procedures with phacoemulsification were included. Results: A total of 28 XEN® 45 µm and 28 XEN® 63 µm were included. Complete surgical success was achieved in 17 cases (60.7%) in the 45 µm group and in 20 cases (71.4%) in the 63 µm group, with no statistical differences. One year after the surgery, the mean IOP was 13.8 ± 3.3 mmHg for the 45 µm group and 12.4 ± 4.2 mmHg for the 63 µm group (p-value > 0.05). Likewise, the use of glaucoma medication was lowered in the 63 µm device (0.32 ± 0.87) compared to the 45 µm device (0.39 ± 0.86), with no statistical significance. Postoperative hypotony was more frequent in the 63 µm device (39.3%) than in the 45 µm group (28.6%), with no statistical differences. However, hypotony-associated complications (including choroidal detachment, hypotony keratopathy, and hypotony maculopathy) were significantly higher in the 63 µm group (p = 0.011). Conclusions: Although the XEN® 63 µm may offer a greater IOP-lowering effect with better complete surgical success, no significant differences were detected compared to the 45 µm device. Hypotony-related complications were higher in the XEN 63 µm, although most of them resolved with conservative management.


  • Open Access

    Efficacy and Safety of Ab Externo Open Conjunctiva XEN® 63 µm Implantation with a 30G Needle Scleral Tract in Primary Open-Angle Glaucoma

    by Yann Bertolani, Jaume Rigo-Quera, Laura Sánchez-Vela, Olivia Pujol-Carreras, Manuel Amilburu, Antonio Dou, Marta Castany

    Background: This study aimed to assess the efficacy and safety of the 30G needle mediated ab externo open conjunctiva approach for the XEN 63 µm implant in primary open-angle glaucoma. Methods: A retrospective and non-randomized study was conducted on consecutive cases of medically refractory primary open-angle glaucoma treated with standalone ab externo open conjunctiva XEN® 63 µm (North Chicago, Illinois) with one-year follow-up. Results: Twenty-two eyes were included. The mean preoperative intraocular pressure was 21.9 ± 7.2 mmHg, and the mean number of glaucoma medications was 2.4 ± 0.9. All patients underwent mitomycin 0.02% application for 2 min, and Healaflow® (MedicalMix, Spain), was implanted in 11 cases (50%). Complete surgical success was achieved in 14 cases (63.6%). No statistical differences in complete surgical success were noted based on the use of Healaflow®. A significant reduction in intraocular pressure (11.8 ± 3.4 mmHg) and in the number of hypotensive medications (0.2 ± 0.5 mmHg) was observed 1 year after the procedure. Transient hypotony was detected in 31.8% of cases. Complications secondary to hypotony included four cases of serous choroidal detachment and one case of localized hemorrhagic choroidal detachment, the latter associated with hypotonic keratopathy and hypotonic maculopathy. All these complications evolved favorably with conservative management and adjusted topical treatment. Conclusions: This study highlights the efficacy and safety of this approach for the XEN 63 µm implant in medically refractory primary open-angle glaucoma.


  • Open Access

    Ab externo open conjunctiva XEN® 63 μm: a novel surgical alternative in uveitic glaucoma-a case report

    by Yann Bertolani, Júlia Angrill-Valls, Laura Sánchez-Vela, Eric Kirkegaard-Biosca, Antonio Dou, Nieves Martín-Begué, Marta Castany

    Purpose: To describe the efficacy and safety of the ab externo open-conjunctiva XEN® 63 μm gel stent in uveitic glaucoma. Case presentation: A case report of a 15-year-old patient with bilateral uncontrolled uveitic glaucoma secondary to chronic anterior uveitis was presented. Several medical ophthalmological and rheumatological evaluation visits were conducted. Preoperative intraocular pressure was 28 mmHg in the right eye and 32 mmHg in the left eye. She underwent a trabeculectomy in her right eye developing hypotonic maculopathy and decompression retinopathy, requiring surgical revision. Considering the complications endured in the right eye, it was decided to perform an ab externo open-conjunctiva XEN® 63 μm implant in her left eye with no postoperative complications. Postoperative course was uneventful with well-controlled intraocular pressure (11 mmHg) and no progression of glaucomatous damage, one year after the procedure. Anterior segment optical coherence tomography evidenced a well-functioning and non-encapsulated bleb along the follow up. Eventually, there were no postoperative uveitic episodes, with 40 mg Adalimumab as a steroid-sparing agent. Conclusion: Uveitic glaucoma presents both clinical and therapeutic challenges. Traditional surgery such as trabeculectomy may entail postoperative complications such as hypotonic maculopathy and decompression retinopathy. This is the first case reporting the efficacy and safety of ab externo open-conjunctiva XEN® 63 μm implant in uveitic glaucoma, highlighting its potential usefulness in such clinical scenarios.


  • Open Access

    Comment on the Article: Exaggerated immune response to fungal keratitis post-COVID19 vaccination

    by Yann Bertolani, Albert Arnaiz-Camacho, Sara Martín Nalda

  • Choroidal metastasis secondary to follicular thyroid carcinoma successfully managed with larotrectinib: A case report and review of the literature

    by Yann Bertolani, Claudia García-Arumí, Tetiana Goncharova, Albert Arnaiz-Camacho, Jose García-Arumí


  • Successful use of PRGF-endoret® and ILM peeling for full thickness macular hole in MacTel type 2: A case report and review of literature

    by Yann Bertolani, Albert Arnaiz-Camacho, Jorge Fernández-Engroba, Jose García-Arumí, Miguel-Ángel Zapata

    Purpose: To describe the successful use of plasma rich in growth factors (PRGF-Endoret®) and internal limiting membrane peeling for full thickness macular hole in Macular Telangiectasia type 2. Case presentation: A case report of a full thickness macular hole (FTMH) associated with Macular Telangiectasia (MacTel) type 2 is described. 25-G vitrectomy with internal limiting membrane (ILM) peeling and use of (PRGF-Endoret®) was performed. Several ophthalmological visits were conducted and multiple diagnostic tests were carried out including optical coherence tomography (OCT) and fluorescein angiography. A 72-year-old man under follow-up for MacTel type 2 presented with worsening vision in his left eye, with a best visual corrected acuity (BVCA) of 20/80. OCT demonstrated a FTMH in the left eye measuring 264 µm. A 25-gauge pars plana vitrectomy surgery was performed with ILM peeling, use of PRGF-Endoret® and tamponade with 20% sulfur hexafluoride (SF6). Three weeks after surgery, complete anatomical closure was observed with a BVCA of 20/40, which improved to 20/25 one year after the surgery. Conclusions: The use of PRGF associated with ILM peeling may be a useful tool in the treatment of macular holes associated with MacTel Type 2 with excellent anatomical and functional outcomes.


  • Open Access

    Tractional Retinal Detachment Related to Hemoglobin C Trait Retinopathy: A Case Report

    by Xavier Garrell-Salat, Claudia Garcia-Arumi, Yann Bertolani, Sandra Banderas García, Paul Buck, Jose Garcia-Arumi

    Hemoglobin C (HbC) disease is an uncommon disease that is generally considered benign, causing only occasionally painless hematuria, osteomyelitis, and dental abnormalities. Ocular manifestations have rarely been described in these patients. Here we report a novel ophthalmological manifestation of the disease. A 20-year-old woman presented with progressive visual loss in her right eye due to tractional retinal detachment. The left eye was apparently normal, but wide-field fluorescence angiography showed mild peripheral ischemia with multiple vascular abnormalities. Vitrectomy was performed and the systemic workup revealed the presence of hemoglobinopathy C in heterozygous form. HbC disease can be sight-threating due to retinal proliferation, similar to sickle cell retinopathy. Patients affected with this disease should undergo regular surveillance. Ultra-wide angiography is a helpful examination to detect peripheral ischemia in the earlier stages.